Ticker: AURX

Nuo Therapeutics, Inc. (OTCMKTS: AURX) has released its financial results for the second quarter of 2025, revealing both opportunities and challenges ahead. Positive Aspects: Total Revenue: Revenue increased to $700,202 for Q2 2025, up from $364,773 in Q2 2024, showing a growth attributed mainly...

Nuo Therapeutics, Inc. (OTCMKTS: AURX) has released its quarterly report for Q1 2025, which highlights both progress and ongoing challenges for the company. Positive Aspects: Increased Revenues: Product sales reached $484,381, a significant rise from $234,577 in Q1 2024, reflecting growing aware...